Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims
- First Online:
- Cite this article as:
- Lapchak, P.A. Transl. Stroke Res. (2011) 2: 129. doi:10.1007/s12975-011-0074-4
- 658 Views
Acute ischemic stroke (AIS) is a disease of heterogeneity . In patients with strokes of known causes, cardioembolic stroke is the predominant subtype making up 29% of the population, whereas both atheroembolic and lacunar strokes are represented by 16% of the population [2, 3]. Most stroke victims having multiple prevailing conditions prior to the onset of the devastating vascular event, such as hypertension or diabetes [1, 4]. Based upon the patient population enrolled in a few prominent clinical trials, it is estimated that 80–90% of all stroke patients were medicated with a variety of pharmaceuticals including antihypertensives (i.e., β-blockers), angiotensin-converting enzyme (ACE) inhibitors, diuretics, calcium channel antagonists, 3-hydroxy-3-methylglutaryl-coenzymeA (HMG-CoA) reductase inhibitors (i.e., statins), platelet inhibitors (i.e., aspirin, clopidogrel), anticoagulants (i.e., warfarin), and antidepressants at the time of their stroke [1, 4–8]. Despite many preventative measures to reduce stroke incidence, stroke remains the third leading cause of death and leading cause of adult disability in the USA . It is estimated that approximately 0.8 million victims suffer a stroke annually with 18% of victims dying. Even though there is a large population of stroke victims in the USA [9–12] and worldwide , and there is an enormous financial impact and burden to society , the arsenal of armaments to effectively treat stroke is limited to one thrombolytic agent that was originally developed to treat acute myocardial infarction [15–20] and subsequently approved for stroke on the basis of the National Institute of Neurological Disorders and Stroke (NINDS) trial . However, it should be noted that in addition to the use of tissue plasminogen activator (tPA) in Japan, a single non-thrombolytic drug, which will be discussed, is also formally approved as a treatment .
There are two structurally and mechanistically different drugs approved for the treatment of stroke: the thrombolytic tPA (Alteplase®) and the pleiotropic antioxidant, edaravone (Radicut®).
Currently, in the USA, the only Food and Drug Administration (FDA)-approved treatment for acute stroke care is tPA (0.9 mg/kg i.v.), a plasminogen activator that promotes thrombolysis by activating the endogenous fibrinolytic system [22–25], and in 22–40% of patients promotes partial or full recanalization [26–31], but recanalization rates are highly variable. The article by Soltani and colleagues  in this issue of TSR elaborates on the use of sonothrombolysis to promote recanalization, either alone or in combination with tPA, but recanalization may be insufficient therapeutically. There is some evidence that the strategy can be beneficial, as detailed in the article, but technical aspects of ultrasound need to be further evaluated for safety and efficacy.
Although thrombolysis, which was first approved by the FDA in 1996, is now widely accepted as a standard of care, it is still underutilized. It is estimated that 2–4% of AIS patients are being treated with tPA in the USA [33, 34]. While there is no doubt that tPA is quite useful in up to 50% of patients given tPA, that is 1–2% of the stroke patient population, depending on the type of ischemic stroke , tPA is not a breakthrough treatment for stroke, mainly because too few patients are being treated. There are important shortcomings of the drug including the fact that tPA does not confer neuroprotection. Alteplase has been shown to be effective up to 4.5 h after a stroke [5, 35], it is currently FDA-approved for use within a 3 h therapeutic window. Lastly, with tPA treatment, there is a significant risk of hemorrhagic transformation (HT) or intracerebral hemorrhage (ICH) in approximately 3% to 6% of patients treated within 3–4.5 h of a stroke  and the odds ratio for mortality rate increases after 4 h . Nevertheless, the fact that at least one FDA-approved drug could be developed is an important proof of concept and an impetus for further drug development.
In Japan, in addition to the use of tPA at both low (0.6 mg/kg i.v.) and standard (0.9 mg/kg i.v.) doses [37, 38], Edaravone (Radicut®), a lipophilic free radical scavenger is approved by the Japanese Ministry of Health and Welfare (JMHW) to treat stroke patients presenting within 24 h of the attack. Edaravone is currently available in two formulations: injectable edaravone ampoules (30 mg b.i.d, i.v., 14 days), which were first approved in 2001, and the Radicut BAG that was approved in 2010, which delivers the same dose of drug. While edaravone is extensively used in Japan, and reports are surfacing from India and China [21, 39, 40], actual benefit spans from large significant clinical improvements to smaller improvements in clinical function measured using standard stroke scales. Unlike the possibly devastating side effects of tPA, after 18 years of clinical experience with edaravone, the main adverse effect is acute renal failure, which usually resolves after cessation of treatment.
Time to Treat Victims
“Learning is not attained by chance, it must be sought for with ardor and attended to with diligence.” Abigail Adams (1744–1818)
The Learning Curve
Developing novel neuroprotective treatments for stroke has become a daunting task and some even question the validity or usefulness of neuroprotective strategies to treat stroke. Could it be that the right compounds are not being developed?
Almost all neuroprotective strategies to date have attempted a monotherapy against a single target. For example, several stroke clinical trials have evaluated neuroprotective agents which target free radicals [21, 39, 50, 51]; however, the results are mixed. The continuing failure of acute neuroprotective drugs was emphasized in the NXY-059 SAINT II trial report . The concept that a free radical scavenger may eventually be useful is not being challenged in this editorial. Free radicals are an important and very damaging component of the ischemic cascade and need to be suppressed (See edaravone and STAZN discussion).
It is now well accepted by the stroke research community that NXY-059 being a hydrophilic compound that does not readily cross the blood brain barrier (BBB) was an inferior compound to develop to treat stroke and that much of the preclinical and translational data overestimated the efficacy of the drug [52–54]. Moreover, the time to treatment used in the SAINT clinical trial may have exceeded a realistic therapeutic window to achieve efficacy [52, 53].
“People are different. And it is best that way.” Mark Twain (1835–1910)
Modeling the Heterogeneity of Stroke
There are two levels of stroke modeling for drug discovery: (1) in vitro screens used to justify further study of a drug and (2) in vivo models used to justify the initiation of a clinical trial. Historically, the in vitro screen has been directed against a single-target enzyme, receptor, protein, or substance, and very often, the goal was to produce a high-affinity ligand toward that “specific target.” This approach is relatively effective to treat a condition if a single target is the sole cause of damage or dysfunction, but this is not the case with AIS and this must now be recognized and dealt with.
In this issue of TSR, Lapchak and colleagues report on a unique series of in vitro assays to develop and de-risk drug candidates . The drug of focus in the article is Stilbazulenyl nitrone (STAZN) previously identified and studied in some detail by Ginsberg, Becker, Belayev, and colleagues [63–67]. STAZN, unlike NXY-059, has a low oxidation potential and is 300 times more potent than NXY-059 at inhibiting free radical induced peroxidation . In the Lapchak report, STAZN was shown to be a multi-target compound, rather than just act as a free radical scavenger as originally proposed . In two separate in vitro HT-22 hippocampal cell assays, STAZN promoted survival. The first assay used iodoacetic acid (IAA), an irreversible inhibitor of glyceraldehyde 3-phosphate dehydrogenase, which is an enzyme in the glycolytic pathway involved in the synthesis of ATP . The second assay, an oxytosis assay, treated cells with the excitotoxic amino acid glutamate, which in this cell line causes cell death by the depletion of intracellular glutathione (GSH) via inhibition of the cystine/glutamate antiporter [69, 70]. The article, in addition to a few others published by the same team, illustrates the utility of multiple cell assay screening, including the use of immortalized murine hippocampal HT-22 cells, to discover, characterize, and de-risk multi-target compounds [68, 70–73].
A survey of the scientific literature reveals that there are a few animal models currently being used that can model the heterogeneity of stroke with respect to the diverse population of patients that can present following a stroke. Based upon the original NINDS tPA clinical trial report now published over 15 years ago, the patient population included in the placebo control group had National Institutes of Health Stroke Scale (NIHSS) scores of 1–32 and the active drug group ranged from 1–37 . In essence, both groups had patients that encompassed almost the complete range of the NIHSS scores, which is a 1-to-42-point scale [1, 74]. The report details that the victims also had various types of stroke and that tPA was effective in cardioembolic stroke (absolute improvement, 9%), large vessel stroke (absolute improvement, 15%), and small vessel stroke (absolute improvement, 14%) . The recent TOAST analysis demonstrated that tPA efficacy in cardioembolic, thromboembolic, and small vessel lacunar strokes was comparable .
There are a few research groups using heterogeneous models of stroke for translational purposes, to assess neuroprotection and/or behavioral improvement [53, 76, 77]. The current gold standard rabbit embolic stroke model  is discussed in detail by the Sharp group  in this issue of TSR. The authors emphasize the importance of using a heterogeneous animal model of stroke for further stroke drug development using clinically relevant endpoints. Of importance are the following suggestions from the group: (1) Death should be included as an endpoint; (2) if possible, studies should be done in the absence of anesthetics, since commonly used anesthetics have significant neuroprotective properties that may confound data [79–82], and (3) tPA should be used as the gold standard in translational development studies. These three salient points were echoed from a previous perspective article in TSR .
There are two rabbit model studies in this issue of TSR, one of which studied the effects of dipyridamole on circulation and behavior in rabbits  and the second which is a technical study measuring nitrite as a biomarker of AIS . The first study used standard clot placement while under 5% isoflurane to study the pretreatment effects of dipyridamole. The second study by Silver and Lapchak  used a variation of a model described by Lapchak . One point of interest in the study  is the absence of anesthetic during embolization and the heterogeneity of infarct distribution (and hemorrhage) in brain following large clot embolization. The distribution is reminiscent of that described in numerous previous publications [53, 86]. There may be a benefit of such a heterogeneous distribution of infarcts in brain following a stroke and a diverse extent of ischemia in brain. As documented in the NINDS tPA study , there is patient population heterogeneity. This type of heterogeneity should be reproduced as much as possible in an animal model to encompass all patients presenting for a clinical trial.
Pleiotropic Drug Discoveries
This section will focus on three additional examples of new drug strategies to treat stroke. STAZN was previously discussed in a section pertaining to useful in vitro screens to uncover pleiotropic activities. While not approved by the FDA, edaravone is approved by the JMHW and is slated for development in North America . Based upon years of preclinical research, data have accumulated which indicate that edaravone is a multi-target drug that may be useful to treat stroke. Edaravone has recently been reviewed in detail . The benefit of edaravone may be due to its antioxidant activity as well as the regulation of signaling pathways. Edaravone has been shown to suppress apoptosis, counteract microglia-induced neurotoxicity, and reduce the long-term inflammation. As an antioxidant, edaravone inhibits lipid oxidation and suppresses the oxidation of low-density lipoprotein. In animals, edaravone reduces edema, possibly by reducing aquaporin-4 levels. Lastly, edaravone reduces the activity of matrix metalloproteinase-9 (MMP-9), and protect against vascular damage and intracerebral hemorrhage (ICH). Thus, these mechanisms may allow edaravone to prevent neuronal degeneration, vascular compartment damage, and behavioral deficits following a stroke .
There is a great deal of literature regarding the beneficial of curcuminoids [89, 90]. Please see the reviews for detailed references [89, 90]. Briefly, like edaravone, curcuminoids have diverse mechanisms of action. Curcumin is an antioxidant, can prevent BBB damage, is also anti-apoptotic, and can both block capsase-3 activation and increase Bcl-2. Like edaravone, curcumin reduces edema and is anti-inflammatory. Lastly, it is postulated that curcumin may repair damaged brain pathways by enhancing the levels of endogenous brain-derived neurotrophic factor (BDNF) and activating TrkB-mediated signaling pathway [91, 92]. In a recent study, Lapchak et al.  showed that a novel designer curcuminoid CNB-001 with enhanced BBB penetration could attenuate cell death mediated by a variety of insults and maintain mitochondrial function. The drug also attenuated behavioral function deficits following embolic strokes, which were correlated with activation of BDNF-related signaling mechanisms .
The last drug is minocycline, which is reviewed in some detail in this issue of TSR . Minocycline has anti-inflammatory properties, anti-apoptotic activity, and is a neuroprotective agent. As described by Fagan et al. , the beneficial effects of minocycline are produced via inhibition of inducible form of nitric oxide synthase (iNOS) and mitogen-activated protein (MAP) kinase, inhibition of glutamate toxicity, and inhibition of microglial activation. The anti-apoptotic effects of minocycline are produced through via attenuation of caspase-1 activation. Importantly, minocycline also decreases MMP-9 activity.
Taken together, these are five excellent examples of pleiotropic drugs that can intervene at multiple steps in the ischemic cascade to confer neuroprotection and behavioral improvement. Since it is still early in the development of this class of drug, it is difficult to conclusively list the properties of the best drug that should be designed to treat stroke. The curcuminoids, both curcumin and CNB-001, may have the advantage of promoting neuronal repair by regulating endogenous trophic factors. All of these pleiotropic drugs require additional translational development and de-risking studies [62, 73, 94] to determine how they can best be used in a clinical situation to provide benefit to stroke victims.
When one considers the urgency of the situation to develop effective stroke treatment, the quote at the beginning of this editorial, which is attributed to John D. Rockefeller, is more than apropos. As a research community dedicated to providing stroke victims with a choice of effective medical care, we must have the opportunity and funding necessary to explore new treatment strategies that are not on the beaten path. The beaten path approach has not been proven to be successful and has thus failed many stroke victims that enrolled in randomized clinical trials.
As highlighted in this editorial, there may be significant advantages to the use of heterogeneous embolic stroke models for drug evaluation of pleiotropic multi-target compounds because of the complexity of the disease [41, 42] that we are attempting to treat. A reasonable alternative to the use of pleiotropic multi-target compounds would be combination therapy, a strategy that may be useful clinically [57, 95–97] to provide synergy or increase the therapeutic window or safety profile for tPA. In the foreseeable future, it is even likely that multiple pleiotropic drugs will be combined to treat stroke. We should remain optimistic about the future of therapy development for AIS and continue to explore new scientific strategies to provide optimal care to stroke victims.
The author was supported by the National Institutes of Neurological Disorders and Stroke Translational Stroke grant 1U01 NS60685-02 (PAL).